Abstract
The past decade has seen remarkable advances in the treatment of rheumatoid arthritis. Although this is good news for the majority of patients, one consequence is that the environment for the development of new drugs has become difficult as a result of high expectations for efficacy. Nevertheless, there remains a subgroup of patients with rheumatoid arthritis who are not candidates for treatment with the newer biologic agents and in whom oral DMARDs have certain advantages. A recent report by Bruyn et al. suggests that the proliferation-signal inhibitor everolimus could have unique properties, in addition to a convenient once-daily oral dosing schedule, that might fit this niche in the therapeutic armamentarium. Further studies are required, however, to confirm the disease-modifying effects and adverse event profile of this drug.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
Arthritis Research & Therapy Open Access 02 October 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
El-Gabalawy HD and Lipsky PE (2002) Why do we not have a cure for rheumatoid arthritis? Arthritis Res 4 (Suppl 3): S297–S301
Saag KG et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59: 762–784
Richards IM et al. (1988) A survey of renal function in outpatients with rheumatoid arthritis. Clin Rheumatol 7: 267–271
Karie S et al. (2008) Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 47: 350–354
Bruyn GAW et al. (2008) Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept study. Ann Rheum Dis 67: 1090–1095
ClinicalTrials.gov [www.clinicaltrials.gov/ct2/results?term=everolimus &recr=Open] (accessed 12 November 2008)
Stone GW et al. (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299: 1903–1913
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has declared that she has received grant/research support from Roche and Genentech
Rights and permissions
About this article
Cite this article
Olsen, N. Is there a role for everolimus in the treatment of RA?. Nat Rev Rheumatol 5, 68–69 (2009). https://doi.org/10.1038/ncprheum0980
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0980
This article is cited by
-
Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
Arthritis Research & Therapy (2023)